brigatinib: Clinical Trials

23 trials of brigatinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 5 recruiting, 5 withdrawn, 3 terminated. 23 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 223Completed 5, Recruiting 5, Withdrawn 5, Terminated 3, Unknown 3, Active not recruiting 2
Phase 13Completed 1, Recruiting 1, Withdrawn 1

Follow brigatinib: new trials by email Literature Review of brigatinib trials Research Report on brigatinib

Trials (filtered) newest first · largest first

All 23 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Using Tumor Models to Determine Treatments
Cobimetinib, Ponatinib, Brigatinib - Pancreatic Ductal Carcinoma, Advanced Cancer
Phase 2RecruitingUniversity Health Network, Toronto252025-04-072026-06-23
Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)
Brigatinib, Carboplatin, Pemetrexed - Non-small Cell Lung Cancer
Phase 2WithdrawnM.D. Anderson Cancer Center2024-12-112025-04-24
Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer
Brigatinib, Durvalumab - NSCLC, Stage III, ALK-rearrangement
Phase 2WithdrawnETOP IBCSG Partners Foundation2024-06-072024-10-08
Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
Brigatinib - Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor
Phase 1 / Phase 2RecruitingPrincess Maxima Center for Pediatric Oncology652022-08-182025-12-05
A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.
Brigatinib - Non-small Cell Lung Cancer
Phase 2UnknownYonsei University122022-06-012022-05-04
Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)
Brigatinib 180 MG, Carboplatin, Pemetrexed - Non Small Cell Lung Cancer, ALK Gene Mutation
Phase 2Active not recruitingIntergroupe Francophone de Cancerologie Thoracique1102022-05-182025-11-17
ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
Crizotinib - Non-small Cell Lung Cancer
Phase 2RecruitingHunan Province Tumor Hospital902021-11-132024-09-20
Brigatinib Before Brain Irradiation Trial (B3i Trial)
Brigatinib - Brain Metastases, Lung Cancer
Phase 2TerminatedUniversity of Colorado, Denver12020-11-172022-10-24
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
Erlotinib, Trastuzumab, Trastuzumab emtansine - Breast Cancer, Gastrointestinal Cancer
Phase 2UnknownFondazione per la Medicina Personalizzata4002020-10-072023-10-03
Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
Brigatinib, Brigatinib AAF - Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors
Phase 1 / Phase 2WithdrawnTakeda2020-09-012020-03-05
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Brigatinib, Neratinib, Retifanlimab - Neurofibromatosis Type 2, Vestibular Schwannoma
Phase 2RecruitingScott R. Plotkin, MD, PhD1092020-06-202026-11-12
Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays
Brigatinib - Non Small Cell Lung Cancer
Phase 2UnknownJI-YOUN HAN352020-05-152023-09-28
Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients
Brigatinib - Lung Cancer, NSCLC
Phase 2Active not recruitingFundación GECP332020-05-042026-02-04
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
Osimertinib, Alectinib 150 MG, Crizotinib 250 MG - Non Small Cell Lung Cancer, EGFR Gene Mutation
Phase 2RecruitingHunan Province Tumor Hospital60002020-04-162024-10-22
Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping
Brigatinib, Tyrosine kinase inhibitor - NSCLC
Phase 2CompletedInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest1182020-03-302026-06-23
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
Alectinib, Brigatinib, Carboplatin - Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Phase 2TerminatedNational Cancer Institute (NCI)102019-07-252026-04-23
Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers
Brigatinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment - Advanced Malignant Neoplasm, ALK Fusion Protein Expression
Phase 2WithdrawnSameek Roychowdhury2019-03-202022-02-18
A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
Brigatinib - ALK-positive Advanced NSCLC
Phase 2CompletedAriad Pharmaceuticals1032019-01-312025-07-31
Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma
Brigatinib - Anaplastic Large Cell Lymphoma, ALK-Positive
Phase 2WithdrawnFox Chase Cancer Center2018-12-062021-01-05
Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)
Brigatinib - ALK-positive Advanced NSCLC
Phase 2CompletedTakeda1042018-01-292024-05-08

Showing 20 of 23. Sign in to see all of them.

Conditions studied

Carcinoma, Non-Small-Cell Lung (12)  ·  Lymphoma, Large-Cell, Anaplastic (4)  ·  Lung Neoplasms (3)  ·  Brain Neoplasms (2)  ·  Breast Neoplasms (1)  ·  Carcinoma (1)  ·  Carcinoma, Pancreatic Ductal (1)  ·  Ependymoma (1)  ·  Gastrointestinal Neoplasms (1)  ·  Granuloma, Plasma Cell (1)  ·  Meningioma (1)  ·  Neoplasm Metastasis (1)  ·  Neurofibromatosis 2 (1)  ·  Neuroma, Acoustic (1)

Sponsors

Ariad Pharmaceuticals (3)  ·  Hunan Province Tumor Hospital (2)  ·  Takeda (2)  ·  Criterium, Inc. (1)  ·  ETOP IBCSG Partners Foundation (1)  ·  Fondazione per la Medicina Personalizzata (1)  ·  Fox Chase Cancer Center (1)  ·  Fundación GECP (1)  ·  Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1)  ·  Intergroupe Francophone de Cancerologie Thoracique (1)  ·  JI-YOUN HAN (1)  ·  M.D. Anderson Cancer Center (1)  ·  National Cancer Institute (NCI) (1)  ·  Princess Maxima Center for Pediatric Oncology (1)  ·  Sameek Roychowdhury (1)

Countries

United States (7)  ·  France (4)  ·  China (3)  ·  Italy (3)  ·  South Korea (3)  ·  Spain (3)  ·  Canada (2)  ·  Germany (2)  ·  Japan (2)  ·  Netherlands (2)  ·  Australia (1)  ·  Austria (1)  ·  Hong Kong (1)  ·  Poland (1)  ·  Sweden (1)

Top investigators

Yongchang Zhang, MD (2)  ·  Andrea Botticelli (1)  ·  Chad Rusthoven, MD (1)  ·  Jessica J Lin (1)  ·  Mariano Provencio, MD (1)  ·  Michel Zwaan, Prof (1)  ·  Paolo Marchetti (1)  ·  Rafal Dziadziuszko, MD (1)  ·  Robert C. Grant, MD (1)  ·  Salah-Eddin Al-Batran, Prof. (1)  ·  Sameek Roychowdhury, MD (1)

Results publications

PMID 29768119, PMID 41110382, PMID 23411383, PMID 27836716, PMID 31125274, PMID 33039599, PMID 33569983, PMID 34182952, PMID 36036294, PMID 36096442, PMID 38904277, PMID 41023484, PMID 41963505

NIH funding

2018 (2), 2019 (1), P30CA016058 (1), P30CA046934 (1), U10CA180868 (1)